

Drug Utilization Review Board Meeting Minutes
November 19, 2014

The West Virginia Medicaid Drug Utilization Review (DUR) Board meeting was called to order with the following in attendance:

Members Present:

Lester Labus, MD., Chair
Kc Lovin, PA-C, Vice Chair
C.K. Babcock, PharmD
Scott Brown, RPh, (via phone)
Karen Fitzpatrick, MD
Michel Lonsinger, PharmD
Ernest Miller, DO,
Mary Nemeth-Pyles, MSN, RN, CS
Pat Regan, PharmD
Chris Terpening, PharmD, PhD
John Vanin, MD
Kate Forman, PharmD

Members Absent:

Myra Chiang, MD

DHHR/BMS Staff Present:

Vicki Cunningham, RPh, Director of Pharmacy Services
Brian Thompson, MS, PharmD, DUR Coordinator
Bill Hopkins, Pharmacy Operations Manager
Doug Sorvig, Administrative Assistant

Contract Staff:

Steve Small, M.S., RPh, Rational Drug Therapy Program (RDTP)
Eric Sears, RPh, Molina Medicaid Solutions
Nina Bandali, PharmD, Magellan Healthcare
Giovanni Perri, MD, Magellan Healthcare
Steve Espy, RPh, CPh, Health Information Design (HID)

- I. **INTRODUCTIONS** - Dr. Lester Labus, Chairman, welcomed everyone to the Board meeting. Dr. Labus welcomed 1 new member to the DUR board, Dr. Kate Forman. Board and attendees introduced themselves. Dr. Labus also acknowledged a prospective new member of the board, Christopher Booth, PharmD.

- II. **OLD BUSINESS**
 - A. None

- III. **NEW BUSINESS**
 - A. **Speakers:**
 - 1 Chris Evangelista – AstraZeneca - Pulmicort Flexhaler

- 2 Sara Noble – Allergan - Restasis
- 3 Tanner Odom – Biogen - Tecfidera
- 4 Kent Hunter – Pfizer - Xeljanz
- 5 Paul Miner – Gilead - Harvoni
- 6 Ndidi Yaucher – Novartis - Gilenya (during open session)

B. Updates from October 22, 2014 P&T Committee Meeting:

- 1 Dr. Labus reviewed the changes from the P&T meeting, and a motion was made, seconded and approved to accept the suggested changes.
- 2 Changes: None
- 3 Attachment A

C. Prior Authorizatio Criteria

- 1 Anoro Ellipta – Motion to approve was made, seconded and passed with changes.
 - a Remove mention of example drugs, and just have the class that is needed for trials.
- 2 Evzio- Motion to approve was made, seconded and passed.
 - a A question was raised as to what information was contained on the Opioid Overdose Risk Assessment Checklist Form. This form was presented to the board after the completion of the presentation by HID.
- 3 Harvoni- Motion to approve was made, seconded and passed.
- 4 Humira (and Enbrel) – Motion to approve was made, seconded and passed with changes.
 - a #5 – Add “concurrent or consecutive” to trial criteria.
 - b #5 – Add “unless contraindicated” to criteria.
- 5 HyQvia - Motion to approve was made, seconded and passed.
- 6 Grastek, Oralair & Ragwitek - Motion to approve was made, seconded and passed with changes
 - a Add a date indicating when the earliest PA would be granted.
- 7 MS Agents - Motion to approve was made, seconded and passed.
- 8 Restasis - Motion to approve was made, seconded and passed with changes
 - a #2 – Change to “PA must be obtained by an ophthalmologist or optometrist.”

Attachment B

IV. REPORTS

- A. Molina Quarterly Report –Second Quarter 2014** - Eric Sears gave an overview of the Molina 2014 Third Quarter Report. The presentation included a review of the DUR Quarterly Overall Summary Report.
See Attachment C

B. **Rational Drug Therapy Program** - Steve Small gave a slide presentation overview of the program activities for the third quarter. The presentation included September and October.

See Attachment D

C. **HID** – Steve Espy gave a slide presentation overview of West Virginia’s Pharmacy Program as compared to 2 other comparable states that HID manages.

See Attachment E

VI. **OTHER BUSINESS - OPEN TO THE FLOOR**

A. Dr. Labus approved a late arriving speaker (#6 on above list) to speak on Gilenya.

B. A motion was made, seconded and approved to keep the Gilenya PA criteria as previously presented and approved.

VII. **NEXT MEETING AND ADJOURNMENT**

A. A motion was made, seconded and approved to adjourn the meeting.

B. The meeting concluded at 6:15p.m.

C. The next meeting will be Wednesday, February 25, 2015 from 4:00 PM-6:00 PM located at the WVDHHR.

Submitted by:

Brian M. Thompson, PharmD